-
Global Biotechnology & Pharmaceutical Markets1 month agoAdvocacy group pokes holes in Trump’s MFN pricing claims
Public Citizen says claims for the drug price savings that are being delivered by Trump's Most Favoured Nation deals with pharma are "a mirage."
-
Global Biotechnology & Pharmaceutical Markets1 month agoOrganon-commissioned survey finds 1 in 3 UK women feel their migraine pain not taken seriously
One in three women in the U.K. feel their migraine pain “is taken less seriously by others because of their gender.”
-
Global Biotechnology & Pharmaceutical Markets1 month agoH5N1 Spreads Among Australian Wildlife as Flu Season Ramps Up
Australia is closely monitoring the H5N1 influenza strain after detections in sea lions, seals, dolphins, and foxes, prompting surveillance for mammal adaptation while authorities report low...
-
Global Biotechnology & Pharmaceutical Markets1 month agoA hidden tradeoff in Trump’s MFN drug deals
The government has announced pricing agreements with 26 pharma companies. But the deals could stymie other plans to lower the country’s drug spend.
-
Global Biotechnology & Pharmaceutical Markets1 month ago
New MFN deal details reignite concerns that Trump’s pricing policy favors pharma
Amid lawmaker and advocacy group efforts to parse the White House’s “most favored nation” drug pricing deals with drugmakers, newly revealed—yet heavily redacted—information is reigniting concerns...
-
Global Biotechnology & Pharmaceutical Markets1 month ago
China targets 25% share of global first-in-class drugs in new 5-year plan
China is aiming to account for at least 25% of first-in-class drugs as part of a five-year push to cement its emerging status as a hotbed...
-
Global Biotechnology & Pharmaceutical Markets1 month agoTelomerase and β-Catenin Join Forces to Drive Aggressive Liver Cancer
Two of the most common genetic alterations in liver cancer have been shown to act as powerful partners in crime, according to a new study published...
-
Global Biotechnology & Pharmaceutical Markets1 month agoChina plans to transform $3M biotech sector into $522B powerhouse by 2030
A new five-year biotech plan has been released by the Chinese government, revealing ambitious goals such as achieving five blockbuster medicines on the global markets in...
-
Global Biotechnology & Pharmaceutical Markets1 month ago
Europe’s CHMP endorses slew of new medicines, including new offerings from Novo and AZ
The CHMP recommendation for Novo's next gen hemophilia A treatment was one of several noteworthy endorsements made by the EU agency this week.
-
Global Biotechnology & Pharmaceutical Markets1 month agoMPs seek probe into UK-US pharma deal’s impact on NHS
The chairs of six UK parliamentary committees have asked the National Audit Office to investigate the UK-US pharma deal and its impact on the NHS.
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
